A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lux Biosciences, Inc.

Criteria

Inclusion Criteria:

• Documented history of non-infectious anterior, anterior and intermediate- or panuveitis

• Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated.

• Grade of 2+ or higher for anterior chamber cells at time of enrollment

• Considered by the investigator to require corticosteroid-sparing therapy.

• Subjects not planning to undergo elective ocular surgery during the study

Exclusion Criteria:

• Uveitis of infectious etiology

• Presence of an ocular toxoplasmosis scar

• An immune suppression regimen that includes an alkylating agent within the previous 90 days